Holen Sie sich die Stockscreener-App
6.82
1.30%
-0.09
Schlusskurs vom Vortag:
$6.91
Offen:
$6.94
24-Stunden-Volumen:
908.18K
Relative Volume:
0.45
Marktkapitalisierung:
$1.13B
Einnahmen:
$246.03M
Nettoeinkommen (Verlust:
$-32.00M
KGV:
-32.09
EPS:
-0.2125
Netto-Cashflow:
$-16.78M
1W Leistung:
-2.71%
1M Leistung:
-11.54%
6M Leistung:
-6.32%
1J Leistung:
+89.44%
1-Tages-Spanne:
$6.80
$7.10
1-Wochen-Bereich:
$6.78
$7.26
52-Wochen-Spanne:
$3.5101
$10.08
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Firmenname
Xeris Biopharma Holdings Inc
Sektor
Branche
Telefon
844-445-5704
Adresse
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
6.82 | 1.15B | 246.03M | -32.00M | -16.78M | -0.2125 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-08-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-11-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | Eingeleitet | Oppenheimer | Outperform |
| 2023-08-28 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-21 | Eingeleitet | Jefferies | Buy |
| 2022-04-28 | Eingeleitet | Craig Hallum | Buy |
| 2021-11-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-02-18 | Eingeleitet | Piper Sandler | Overweight |
| 2018-07-16 | Eingeleitet | Jefferies | Buy |
| 2018-07-16 | Eingeleitet | Leerink Partners | Outperform |
| 2018-07-16 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Xeris Biopharma Holdings Inc Aktie (XERS) Neueste Nachrichten
Earnings Report: Does Xeris Biopharma Holdings Inc. stock benefit from AI growthJuly 2025 Reactions & Stock Market Timing Techniques - mfd.ru
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Institutional Investors Lost 4.6% Over the Past Week but Have Profited From Longer-term Gains - 富途牛牛
How Xeris’ Diversified Product Portfolio and XP-8121 Progress Could Shape Xeris Biopharma (XERS) Investors - Sahm
Xeris Biopharma (NASDAQ:XERS) and Metagenomi (NASDAQ:MGX) Critical Comparison - Defense World
Xeris Biopharma: Strong Recorlev Momentum And Pipeline Opportunity (XERS) - Seeking Alpha
Y Intercept Hong Kong Ltd Lowers Holdings in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Xeris Biopharma (NASDAQ:XERS) Insider Beth Hecht Sells 16,667 Shares - MarketBeat
Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: Unlocking a 53.91% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Market Trends: What is the implied volatility of Xeris Biopharma Holdings IncTrade Entry Report & Smart Swing Trading Alerts - baoquankhu1.vn
Buy Signal: Can RNST keep up with sector leadersJuly 2025 Market Mood & Growth Focused Entry Reports - baoquankhu1.vn
Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: Exploring a 46% Potential Upside for Investors - DirectorsTalk Interviews
A Look At Xeris Biopharma Holdings (XERS) Valuation After Its Updated 2025 Revenue Outlook - Sahm
Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: Unveiling a 50% Potential Upside in Biotech - DirectorsTalk Interviews
Does Xeris Biopharma (XERS) Boosted 2025 Revenue Guidance Strengthen Its Commercial Momentum Narrative? - simplywall.st
How Investors Are Reacting To Xeris Biopharma (XERS) Raising 2025 Revenue Outlook And Recorlev Momentum - Sahm
Technical Analysis: What are Xeris Biopharma Holdings Incs technical support levels2025 Price Momentum & Smart Investment Allocation Insights - baoquankhu1.vn
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is It Too Late To Consider Xeris Biopharma Holdings (XERS) After Its 133% One-Year Surge? - Yahoo Finance
Assessing Xeris Biopharma Holdings (XERS) Valuation After Strong Recent Shareholder Returns - Yahoo Finance
Is Xeris Biopharma Holdings (XERS) Price Rally Still Justified After Recent Company Updates - Sahm
Why Xeris Biopharma Holdings (XERS) Is Up 7.9% After Raising 2025 Revenue Outlook and Adding Patents - Yahoo Finance
XERS: HC Wainwright & Co. Reiterates Buy Rating with $10.00 Pric - GuruFocus
Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells 15,000 Shares of Stock - MarketBeat
Xeris Biopharma (NASDAQ:XERS) Earns Buy Rating from HC Wainwright - MarketBeat
Published on: 2026-01-13 01:49:04 - ulpravda.ru
Xeris Biopharma (XERS) Exceeds 2025 Revenue Expectations - GuruFocus
Will Xeris Biopharma Holdings Inc. stock outperform tech sector in 20252025 EndofYear Setup & Weekly High Potential Stock Alerts - Улправда
Breakout Move: Is Xeris Biopharma Holdings Inc. stock a smart buy before Fed meetingJuly 2025 Trade Ideas & AI Driven Price Predictions - Улправда
How Xeris Biopharma Holdings Inc. stock benefits from strong dollarJuly 2025 Update & AI Powered Buy and Sell Recommendations - Улправда
Is Xeris Biopharma Holdings Inc. stock positioned well for digital economyBreakout Watch & Smart Allocation Stock Reports - Улправда
Xeris Biopharma expects full-year 2025 revenue above estimates - MSN
Xeris Biopharma (NASDAQ:XERS) Shares Gap UpHere's Why - MarketBeat
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue - BioSpace
Xeris Biopharma Holdings, Inc. Updates Earnings Guidance for the Full-Year 2025 - marketscreener.com
A biotech treating 700 patients is on track for a record revenue year - Stock Titan
Xeris Biopharma director Shannon sells $176k in shares By Investing.com - Investing.com UK
Xeris Biopharma director Shannon sells $176k in shares - Investing.com
Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock - MarketBeat
Xeris Biopharma Holdings, Inc. $XERS Shares Sold by Diversified Trust Co - MarketBeat
This Small Biotech Stock Is Still a Buy After Massive Bottom-Line Gift - TheStreet Pro
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
Xeris Biopharma (NASDAQ:XERS) Trading Down 6.8%Time to Sell? - MarketBeat
Calamos Advisors LLC Makes New Investment in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday - Finviz
Is Xeris Biopharma on the Verge of a Breakthrough? - StocksToTrade
Xeris Biopharma Holdings Inc. (XERS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Finanzdaten der Xeris Biopharma Holdings Inc-Aktie (XERS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Xeris Biopharma Holdings Inc-Aktie (XERS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| McCulloch Kevin | See Remarks |
Jan 08 '26 |
Sale |
8.00 |
15,000 |
120,000 |
1,685,426 |
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):